Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
10-year follow-up of Cervarix immunogenicity and safety after study HPV-014
2009-011357-41Phase 3Completed
- Sponsor
- GSK
- Start
- May 2009
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of human papillomavirus type 16 L1 capsid protein antigen in human papillomavirus infection and Cervical Cancer (CC), sponsored by GSK. Primary endpoints: Immune responses to vaccine components and Long-term immunogenicity by ELISA. Started May 2009; status: completed.
02
Drugs
human papillomavirus type 16 L1 capsid protein antigen
03
Conditions
human papillomavirus infectionCervical Cancer (CC)
Beyond the preview
Go deeper on 2009-011357-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011357-41.